MicroRNA‑873 inhibits the proliferation and invasion of endometrial cancer cells by directly targeting hepatoma‑derived growth factor Retraction in /10.3892/etm.2022.11475

Wang,Qin; Zhu,Weipei

doi:10.3892/etm.2019.7713

MicroRNA‑873 inhibits the proliferation and invasion of endometrial cancer cells by directly targeting hepatoma‑derived growth factor

Retraction in: /10.3892/etm.2022.11475

Authors:
- Qin Wang
- Weipei Zhu
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, The First People's Hospital of Kunshan, Kunshan, Jiangsu 215000, P.R. China, Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
Published online on: June 26, 2019 https://doi.org/10.3892/etm.2019.7713
Pages: 1291-1298

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An accumulation of evidence has demonstrated that abnormal microRNA (miRNA or miR) expression is associated with different types of cancer, including endometrial cancer (EC). The dysregulation of miRNAs may serve important roles in the development and progression of EC by regulating multiple aggressive biological behaviors, including cell proliferation, apoptosis, metastasis and angiogenesis. An in‑depth understanding of the miRNAs associated with EC initiation and progression may be crucial for identifying successful therapeutic techniques. miR‑873 has been demonstrated to be dysregulated in different types of cancer. However, the expression status and regulatory roles of miR‑873 are yet to be elucidated in EC. In the present study, reverse transcription‑quantitative PCR was carried out to detect miR‑873 expression in EC tissues and cell lines. Cell Counting Kit‑8 and in vitro invasion assays were utilized to determine the influence of miR‑873 on the proliferation and invasion of EC cells. miR‑873 expression was revealed to be downregulated in EC tissues and cell lines. Decreased miR‑873 expression was significantly associated with International Federation of Gynecology and Obstetrics stage and lymph node metastasis of patients with EC. Functional assays revealed that resumed miR‑873 expression suppressed the proliferation and invasion of EC cells. Additionally, hepatoma‑derived growth factor (HDGF) was indicated to be a direct target gene of miR‑873 in EC cells. HDGF was highly expressed in EC tissues and inversely correlated with miR‑873 expression. HDGF silencing also imitated the tumor‑suppressor activity of miR‑873 overexpression in EC cells. A series of rescue experiments identified that recovered HDGF expression hindered the anti‑proliferative and anti‑invasive roles of miR‑873 upregulation in EC cells. In conclusion, the present study indicated that miR‑873 serves an important role as a tumor suppressor in EC development by directly targeting HDGF. The results may provide a novel insight into clinical treatments, which can be used to prevent EC aggression.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Dizon DS: Treatment options for advanced endometrial carcinoma. Gynecol Oncol. 117:373–381. 2010. View Article : Google Scholar : PubMed/NCBI
3	Bendifallah S, Ballester M and Darai E: Endometrial cancer: Predictive models and clinical impact. Bull Cancer. 104:1022–1031. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
4	Fong P and Meng LR: Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status. Med Sci Monit Basic Res. 20:146–152. 2014. View Article : Google Scholar : PubMed/NCBI
5	Vale CL, Tierney J, Bull SJ and Symonds PR: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. CD0039152012.PubMed/NCBI
6	Boll D, Verhoeven RH, van der Aa MA, Pauwels P, Karim-Kos HE, Coebergh JW and van Doorn HC: Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989–2008. Int J Gynecol Cancer. 22:599–606. 2012. View Article : Google Scholar : PubMed/NCBI
7	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
8	Lai EC: Micro RNAs are complementary to 3′UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI
9	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
10	Chen S, Sun KX, Liu BL, Zong ZH and Zhao Y: MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer. 15:112016. View Article : Google Scholar : PubMed/NCBI
11	Link A and Kupcinskas J: MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. World J Gastroenterol. 24:3313–3329. 2018. View Article : Google Scholar : PubMed/NCBI
12	Piasecka D, Braun M, Kordek R, Sadej R and Romanska H: MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018. View Article : Google Scholar : PubMed/NCBI
13	Kushlinskii NE, Fridman MV and Braga EA: Molecular mechanisms and microRNAs in osteosarcoma pathogenesis. Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
14	Rarani FZ, Borhani F and Rashidi B: Endometrial pinopode biomarkers: Molecules and microRNAs. J Cell Physiol. 233:9145–9158. 2018. View Article : Google Scholar : PubMed/NCBI
15	Srivastava SK, Ahmad A, Zubair H, Miree O, Singh S, Rocconi RP, Scalici J and Singh AP: MicroRNAs in gynecological cancers: Small molecules with big implications. Cancer Lett. 407:123–138. 2017. View Article : Google Scholar : PubMed/NCBI
16	Kanekura K, Nishi H, Isaka K and Kuroda M: MicroRNA and gynecologic cancers. J Obstet Gynaecol Res. 42:612–617. 2016. View Article : Google Scholar : PubMed/NCBI
17	Han G, Zhang L, Ni X, Chen Z, Pan X, Zhu Q, Li S, Wu J, Huang X and Wang X: MicroRNA-873 promotes cell proliferation, migration, and invasion by directly targeting TSLC1 in Hepatocellular carcinoma. Cell Physiol Biochem. 46:2261–2270. 2018. View Article : Google Scholar : PubMed/NCBI
18	Gao Y, Xue Q, Wang D, Du M, Zhang Y and Gao S: miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1. Am J Transl Res. 7:2519–2526. 2015.PubMed/NCBI
19	Jin S, He J, Li J, Guo R, Shu Y and Liu P: MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1. Thorac Cancer. 9:1262–1270. 2018. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wang L, Jiang Q, Hua S, Zhao M, Wu Q, Fu Q, Fang W and Guo S: High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma. Dis Markers. 2014:2987952014. View Article : Google Scholar : PubMed/NCBI
22	Yanokura M, Banno K, Iida M, Irie H, Umene K, Masuda K, Kobayashi Y, Tominaga E and Aoki D: MicroRNAS in endometrial cancer: Recent advances and potential clinical applications. EXCLI J. 14:190–198. 2015.PubMed/NCBI
23	Iqbal MA, Arora S, Prakasam G, Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
24	Xiong H, Chen R, Liu S, Lin Q, Chen H and Jiang Q: MicroRNA-183 induces epithelial-mesenchymal transition and promotes endometrial cancer cell migration and invasion in by targeting CPEB1. J Cell Biochem. 119:8123–8137. 2018. View Article : Google Scholar : PubMed/NCBI
25	Kontomanolis EN and Koukourakis MI: MicroRNA: The potential regulator of endometrial carcinogenesis. Microrna. 4:18–25. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhuo Z and Yu H: miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells. Oncotarget. 8:28042–28051. 2017. View Article : Google Scholar : PubMed/NCBI
27	Zhang W, Chen JH, Shan T, Aguilera-Barrantes I, Wang LS, Huang TH, Rader JS, Sheng X and Huang YW: miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. Lab Invest. 98:1397–1407. 2018. View Article : Google Scholar : PubMed/NCBI
28	Liu J, Li C, Jiang Y, Wan Y, Zhou S and Cheng W: Tumor-suppressor role of miR-139-5p in endometrial cancer. Cancer Cell Int. 18:512018. View Article : Google Scholar : PubMed/NCBI
29	Shi W, Wang X, Ruan L, Fu J, Liu F and Qu J: MiR-200a promotes epithelial-mesenchymal transition of endometrial cancer cells by negatively regulating FOXA2 expression. Pharmazie. 72:694–699. 2017.PubMed/NCBI
30	Gong H, Fang L, Li Y, Du J, Zhou B, Wang X, Zhou H, Gao L, Wang K and Zhang J: miR873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1. Oncol Rep. 39:1090–1098. 2018.PubMed/NCBI
31	Cui J, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERalpha transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene. 34:40182015. View Article : Google Scholar : PubMed/NCBI
32	Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
33	Cao D, Yu T and Ou X: MiR-873-5P controls gastric cancer progression by targeting hedgehog-GLI signaling. Pharmazie. 71:603–606. 2016.PubMed/NCBI
34	Liang Y, Zhang P, Li S, Li H, Song S and Lu B: MicroRNA-873 acts as a tumor suppressor in esophageal cancer by inhibiting differentiated embryonic chondrocyte expressed gene 2. Biomed Pharmacother. 105:582–589. 2018. View Article : Google Scholar : PubMed/NCBI
35	Wu DD, Li XS, Meng XN, Yan J and Zong ZH: MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
36	Liao F, Liu M, Lv L and Dong W: Hepatoma-derived growth factor promotes the resistance to anti-tumor effects of nordihydroguaiaretic acid in colorectal cancer cells. Eur J Pharmacol. 645:55–62. 2010. View Article : Google Scholar : PubMed/NCBI
37	Chen SC, Hu TH, Huang CC, Kung ML, Chu TH, Yi LN, Huang ST, Chan HH, Chuang JH and Liu LF: Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis. Oncotarget. 6:16253–16270. 2015.PubMed/NCBI
38	Tsai CC, Huang SC, Tai MH, Chien CC, Huang CC and Hsu YC: Hepatoma-derived growth factor upregulation is correlated with prognostic factors of early-stage cervical adenocarcinoma. Int J Mol Sci. 15:21492–21504. 2014. View Article : Google Scholar : PubMed/NCBI
39	Liu XJ, Liu WL, Yang FM, Yang XQ and Lu XF: Hepatoma-derived growth factor predicts unfavorable prognosis of epithelial ovarian cancer. Onco Targets Ther. 8:2101–2109. 2015.PubMed/NCBI